| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Tapentadol hydrochloride (JAN); Nucynta (TN) | ||||||||
| Product | NUCYNTA (Collegium Pharmaceutical), NUCYNTA (Collegium Pharmaceutical), NUCYNTA (Quality Care Products) | ||||||||
| Formula | C14H23NO. HCl | ||||||||
| Exact mass | 257.1546 | ||||||||
| Mol weight | 257.7995 | ||||||||
| Structure |  | ||||||||
| Simcomp | |||||||||
| Class | Neuropsychiatric agent DG01564 Opioid receptor agonist DG01563 mu-Opioid receptor agonist Analgesic DG01984 Opioid analgesics Metabolizing enzyme substrate DG02924 UGT substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Analgesic, Opioid receptor agonist, Noradrenaline reuptake inhibitor | ||||||||
| Disease | Diabetic peripheral neuropathy (DPN) [DS:H01459] | ||||||||
| Target | OPRM1 [HSA:4988] [KO:K04215] SLC6A2 (NAT1) [HSA:6530] [KO:K05035] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Enzyme: UGT [KO:K00699] | ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N02 ANALGESICS N02A OPIOIDS N02AX Other opioids N02AX06 Tapentadol D10199 Tapentadol hydrochloride (JAN) <JP/US> USP drug classification [BR:br08302] Analgesics Opioid Analgesics, Long-acting Tapentadol D10199 Tapentadol hydrochloride (JAN) Opioid Analgesics, Short-acting Tapentadol D10199 Tapentadol hydrochloride (JAN) Therapeutic category of drugs in Japan [BR:br08301] 8 Narcotics 82 Non-alkaloidal narcotics 821 Synthetic narcotics 8219 Others D10199 Tapentadol hydrochloride (JAN) Drug groups [BR:br08330] Neuropsychiatric agent DG01564 Opioid receptor agonist DG01563 mu-Opioid receptor agonist DG00826 Tapentadol D10199 Tapentadol hydrochloride Analgesic DG01984 Opioid analgesics DG00826 Tapentadol D10199 Tapentadol hydrochloride Metabolizing enzyme substrate DG02924 UGT substrate DG00826 Tapentadol D10199 Tapentadol hydrochloride Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Opioid OPRM1 D10199 Tapentadol hydrochloride (JAN) <JP/US> Transporters Solute carrier family SLC6 SLC6A2 (NAT1) D10199 Tapentadol hydrochloride (JAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10199 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10199 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10199 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10199 Drug groups [BR:br08330] Neuropsychiatric agent DG01564 Opioid receptor agonist DG01563 mu-Opioid receptor agonist DG00826 Tapentadol Analgesic DG01984 Opioid analgesics DG00826 Tapentadol Metabolizing enzyme substrate DG02924 UGT substrate DG00826 Tapentadol | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 17 1 C8y C 17.4300 -17.0800 2 C8x C 17.4300 -18.4800 3 C8x C 18.6200 -19.1800 4 C8x C 19.8800 -18.4800 5 C8y C 19.8800 -17.0800 6 C8x C 18.6200 -16.3800 7 O1a O 16.1700 -16.3800 8 C1c C 21.0700 -16.3800 9 C1c C 22.2600 -17.0800 10 C1b C 21.0700 -14.9800 11 C1b C 23.4500 -16.3800 12 C1a C 22.2600 -14.2800 13 N1c N 24.6400 -17.0800 14 C1a C 22.2600 -18.4800 15 C1a C 25.9000 -16.3800 16 C1a C 24.6400 -18.4800 17 X Cl 29.3300 -18.6200 BOND 16 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 1 7 1 8 5 8 1 9 8 9 1 10 8 10 1 #Down 11 9 11 1 12 10 12 1 13 11 13 1 14 9 14 1 #Down 15 13 15 1 16 13 16 1 |